CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation

CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, 2026. As one of China's most influential national academic meetings in urology, this year's conference adopted the theme "Collaboration and Innovation", bringing together leading domestic and international experts to discuss advances in minimally invasive surgery, robotic technology, precision medicine, and multidisciplinary cancer care, while promoting high-quality specialty development and the translation of scientific advances into clinical practice.
CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He

CUDA 2026 | Rethinking Tiered Healthcare and Multidisciplinary Care in Urology—An Interview with Prof. Zhisong He

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou under the theme "Collaboration and Innovation." The conference focused on key topics including precision diagnosis and treatment of urologic diseases, comprehensive cancer management, and multidisciplinary team (MDT) care, showcasing China's latest advances in technological innovation and the standardization of clinical practice.
CUDA 2026 | Prof. Xingyuan Xiao: Rethinking Comprehensive Urologic Cancer Management Through the Integration of Traditional Chinese and Western Medicine and MDT

CUDA 2026 | Prof. Xingyuan Xiao: Rethinking Comprehensive Urologic Cancer Management Through the Integration of Traditional Chinese and Western Medicine and MDT

The 2026 Annual Meeting of the Chinese Urological Doctor Association (CUDA 2026) was held in Zhengzhou, Henan, from June 11 to 14. Prof. Xingyuan Xiao of Zhongnan Hospital of Wuhan University has long been engaged in the clinical management and research of urologic diseases, with extensive experience in integrating traditional Chinese medicine (TCM) and Western medicine for urologic cancers and treatment-related complications.
CUDA 2026 | Prof. Zhaohui Gu: Advancing Intelligent Surgery and Precision Treatment to Shape the Future of Urology

CUDA 2026 | Prof. Zhaohui Gu: Advancing Intelligent Surgery and Precision Treatment to Shape the Future of Urology

The 2026 Annual Meeting of the Chinese Urological Doctor Association (CUDA 2026) was held in Zhengzhou from June 11 to 14. As one of China’s most influential national academic meetings in urology, this year’s congress highlighted cutting-edge developments in robotic surgery, AI-assisted diagnosis and treatment, precision medicine, and minimally invasive technologies, promoting clinical translation and innovation in urologic care.
Breaking New Ground in Oligometastatic Kidney Cancer | Prof. Liru He’s Team Reports Sunitinib Plus SBRT Strategy in Cell Reports Medicine

Breaking New Ground in Oligometastatic Kidney Cancer | Prof. Liru He’s Team Reports Sunitinib Plus SBRT Strategy in Cell Reports Medicine

The treatment landscape for renal cell carcinoma (RCC), one of the most common malignancies of the urinary system, continues to evolve rapidly, with targeted therapy combined with immunotherapy now established as a standard first-line approach for advanced and metastatic disease. However, for patients with oligometastatic RCC, a standardized treatment strategy has yet to be established.
19th CUA Genitourinary Oncology Conference | Professor Baojun Wang: Breaking Through the Bottlenecks in Prostate Cancer Treatment—Balancing Clinical Innovation with Standardized Care

19th CUA Genitourinary Oncology Conference | Professor Baojun Wang: Breaking Through the Bottlenecks in Prostate Cancer Treatment—Balancing Clinical Innovation with Standardized Care

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting brought together leading experts in urologic oncology from across China to examine the current challenges facing the field and explore future directions for clinical research and patient care.
19th CUA Genitourinary Oncology Conference | Professor Xuesong Li: Advancing the UTUC Subspecialty Through High-Quality Research to Address Key Clinical Challenges

19th CUA Genitourinary Oncology Conference | Professor Xuesong Li: Advancing the UTUC Subspecialty Through High-Quality Research to Address Key Clinical Challenges

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, bringing together leading experts from across China under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting provided a platform for discussing new directions in urologic oncology research and clinical practice.
19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was successfully held in Beijing on July 3–4, 2026. Centered on the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation," the meeting featured in-depth discussions on precision oncology, early screening and prevention of prostate cancer, and the development of a robust domestic clinical research ecosystem, highlighting both the latest advances and the key challenges facing urologic oncology in China.